Image

Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI

Modulation of Hippocampal Circuitry and Memory Function With Focused Ultrasound in Amnestic MCI

Recruiting
50-90 years
All
Phase N/A

Powered by AI

Overview

This study is a proof of concept/proof of mechanism study addressing the hypothesis that Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex can

(A) successfully target and increase activity in the entorhinal cortex and functionally connected brain regions (B) improve connectivity of memory networks (C) improve memory for information (D) have a dose-dependent effect on memory and brain activity.

A secondary objective is to determine the relationship between blood-based AD biomarkers and LIFUP treatment outcomes, and the relationship between magnitude of HC volume decline and LIFUP treatment outcomes.

Description

  • PRÉCIS --- This is a proof of concept/proof of mechanism trial of Low Intensity Focused Ultrasound Pulsation (LIFUP) targeting the entorhinal cortex in patients with amnestic MCI. The study will integrate behavioral and multimodal neuroimaging to assess the utility, dose and duration of LIFUP to a) increase neural activity in deep neural structures and 2) to enhance memory function in patients with amnestic MCI. The intervention will randomly assign subjects to one of four dose conditions (0, 1, 2, or 3 doses). Each dose consists of six 30-second sonications, alternating with 30-second OFF blocks for a total of 6 minutes. Each participant will have two LIFUP sessions with the same condition, spaced 2 weeks apart. Sessions occur within the MRI scanner with pre-sonication ASL and rsfMRI, simultaneous rsfMRI, and post-sonication ASL. Verbal and visuospatial memory will be assessed at baseline, 48 hours after each session via Zoom, and two weeks after the last in-person session.
    • Objectives --- Imaging markers of target modulation: Use fMRI collected simultaneously with LIFUP to assess modulation of neural activity in the hippocampal region and DMN, and ASL pre- and post- LIFUP to assess direct up-regulation of ErC perfusion

Measure LIFUP changes in functional connectivity (change from grant based on reviews: the investigators initially also included cortical thickness changes; current research methods now use CT as a predictor)

Determine whether LIFUP-induced changes in ErC perfusion and ErC/DMN FC will be associated with improved learning and memory

Determine the relationship between AD risk and LIFUP-induced changes: LIFUP-induced functional changes will be associated with blood-based biomarker status (AB42/40 and Ptau217)

---Design and Outcomes --- This is an intervention assessing the effects of focused ultrasound on memory, cerebral blood flow, and functional connectivity in memory circuits in patients with MCI. Patients will be assigned to one of 4 dose groups: 0, 1, 2, or 3 doses at each LIFUP session. At an initial baseline in-person session, subjects will receive structural MRI, a premorbid intelligence test and memory pre-testing. At the second in-person visit, the subjects will undergo a blood draw, pre- and simultaneous resting-state functional MRI and LIFUP sonication, as well as pre- and post-LIFUP ASL to measure blood flow changes. Memory will be assessed remotely 48 hours after the treatment. An identical in-person MRI-LIFUP session and follow-up session will occur 2 weeks later, and a final memory evaluation will occur remotely 2 weeks after the last in-person session. Those administrating memory assessments and analyzing data will be blind to dosage group. The study design section presents a diagram and more detailed description of procedures.

--- Interventions and Duration --- At each of the two MRI-LIFUP sessions, subjects will receive 0, 1, 2, or 3 doses of LIFUP, with each dose consisting of six 30-second sonication blocks.

Eligibility

Inclusion Criteria

  • Amnestic MCI diagnosis
  • Age 50-90
  • English-speaking
  • Right-handed
  • Ability to provide informed consent via UBACC (Jeste et.al., 2007) procedure
  • Normal or corrected-to-normal hearing or vision

Exclusion Criteria

GENERAL

Participation in another clinical trial

        Active use of prescribed medications to improve cognition and/or memory, e.g.,
        cholinesterase inhibitors, memantine, or Aduhelm
        MRI Incompatibility
        Weight exceeding 275 pounds
        Pregnancy, suspicion of pregnancy, or attempting to become pregnant
        Claustrophobia
        Difficulties during previous MRIs
        Top permanent retainer (bottom only is okay)
        5 or more non-removable gold-teeth
        Metal braces, top spacers, and/or palate expanders
        Any of the following implants:
        Aneurysm clips
        Cochlear implants
        Defibrillator
        Electrodes or wires
        Magnetically-activated device
        Spinal cord stimulator
        Infusion or insulin pumps
        Implanted drug infusion device
        Deep brain stimulation device
        Cardiac pacemaker
        Non-removable hairpieces, hairpiece extensions, and/or piercings
        Facial tattoos or permanent makeup
        Metal implants that are MR-incompatible, or where participant is unable to provide
        sufficient information to determine MR compatibility
        Previous injury by metallic foreign body (e.g., bullet, BB, shrapnel) where the object
        entered the body and (one of the following conditions):
        The metallic foreign body wasn't fully removed
        Participant lacks a doctor's confirmation that the metallic foreign body was fully removed
        Diagnosis of one or more of the following neurological disorders:
        Alzheimer's disease
        Parkinson's disease
        Lou Gehrig's disease (ALS)
        Multiple sclerosis
        Cerebral Palsy
        Diagnosis of one or more of the following genetic disorders
        Cystic Fibrosis
        Sickle Cell Disease
        Diagnosis of one or more of the following psychiatric disorders
        Psychosis
        Dementia
        Mental illness other than anxiety or depression
        GAD and depression if they have not been controlled for at least one year (if controlled >1
        year, with or without medication, they are not exclusionary)
        Other Medical
        Severe lung, liver, heart, and/or kidney disease/s (e.g., heart failure, liver failure, and
        etc...)
        Diagnosis of thyroid disorder or change of thyroid medication dose within the last year
        Cancer treatment/s with chemotherapy and/or radiation to head and neck
        Stage 4 (metastatic) cancer
        Treatment/s for:
        Hepatitis
        HIV
        Rheumatoid arthritis
        Lupus
        Any autoimmune disorder
        Treatment/s to prevent transplant rejection
        History of substance abuse
        Including alcohol, but not nicotine or caffeine
        History of stroke
        History of 2 or more seizures or diagnosis of epilepsy, unless the seizures occurred prior
        to age 5 alongside a fever.
        History of brain tumor, brain aneurysm, brain hemorrhage, or subdural hematoma (transient
        ischemic attack not exclusionary)
        History of concussion or similar head injury if any of the following were present:
        Head injury requiring hospitalization
        Head injury succeeded by loss of consciousness for more than 30 minutes
        Head injury succeeded by amnesia, confusion, and/or loss of orientation lasting longer than
        24 hours
        CT scan that revealed brain abnormalities
        2 or more of the following symptoms if they lasted for longer than 3 months after head
        injury
        Headache
        Dizziness
        Hypersomnia or insomnia
        Phono- or photophobia
        Trouble with attention, memory, or staying on task
        Decline in school performance
        Depression and/or anxiety
        Panic attacks
        PTSD
        Uncontrolled high blood pressure or diabetes
        Heart attack within the last year
        Daily use of prescribed migraine medication

Study details
    Mild Cognitive Impairment
    Amnestic Mild Cognitive Disorder
    Deep Brain Stimulation

NCT05417555

University of California, Los Angeles

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.